The Senate passed a cannabis research reform bill 92-4 in February. Fifty-one days later, the House has done nothing with it.
That’s not a parliamentary delay. That’s a choice — and it’s one that directly affects researchers who have been waiting years for the federal government to stop treating cannabis like it’s untouchable. The Cannabidiol and Marihuana Research Expansion Act Reauthorization of 2026, S.1876, would remove the most significant bureaucratic obstacles to studying cannabis in the United States. It passed with the kind of majority that almost never happens on anything. The House hasn’t scheduled a floor vote.
What This Bill Actually Does
The original Cannabidiol and Marihuana Research Expansion Act became law in 2022. It was a meaningful step: it reduced some of the DEA approval barriers that had made running cannabis trials so expensive and slow that most academic institutions simply avoided them. The 2026 reauthorization goes further.
Under current Schedule I rules, researchers studying cannabis face a separate DEA registration process, additional approval layers at the institutional level, and severe restrictions on the types of clinical trials they can run. A physician treating a patient with an FDA-approved drug has none of these constraints. A researcher trying to establish whether that same drug works has to navigate a regulatory gauntlet designed for narcotics trafficking.
S.1876 changes three things specifically: – It allows FDA-approved clinical trials involving cannabis to proceed without requiring redundant DEA-specific scheduling approval for each trial – It expands the number of DEA-licensed cannabis cultivators who can supply research-grade material to academic institutions – It creates a streamlined pathway for existing state-licensed researchers to apply for federal research authorization without starting from scratch
This does not legalize cannabis. It does not move cannabis out of Schedule I. It does not change what dispensaries can sell or what patients can buy. What it does is remove a layer of federal obstruction that has made the United States a second-tier country for cannabis research, while other nations have built clinical infrastructure we lack entirely.
Who It Affects
The immediate beneficiaries are research institutions — the universities, teaching hospitals, and independent clinical research organizations currently unable to run FDA-caliber trials on a substance used by an estimated 50 million Americans annually.
That gap has real-world consequences. VA doctors cannot recommend cannabis to veterans experiencing PTSD or chronic pain, in part because the clinical trial evidence the FDA requires for formal approval has been nearly impossible to generate under the current regime. Pediatric neurologists studying cannabis-derived treatments for treatment-resistant epilepsy still navigate DEA approval timelines that can add 18 months to a study. Oncologists researching cannabinoids for chemotherapy-related nausea — an area where clinical evidence is already promising — face the same structural barriers.
The 92-4 Senate vote suggests there’s virtually no substantive opposition to fixing this. The argument over scheduling cannabis for recreational or adult-use purposes is a different and genuinely contested political fight. The argument over whether researchers should be able to study a substance used by 50 million people has been settled, at least in the Senate.
The Direction
This is unambiguously an access-expanding bill — specifically, access for the research infrastructure that would eventually generate the evidence base that other regulatory decisions rest on. Blocking research doesn’t prevent cannabis use; it prevents knowledge.
It’s also worth naming what this bill is not: it is not SAFE Banking, it is not rescheduling, and it is not legalization. All of those remain stalled in separate legislative lanes. The Research Act was designed to be the easy win — the bill everyone could vote for without triggering the social-conservative backlash that stops broader reform. The 92-4 Senate vote proved the theory. The House’s inaction suggests either the Republican leadership doesn’t want to give the Biden-aligned cannabis reform agenda any victories in an election year, or that no one with floor scheduling authority has made this a priority.
Either way: this is the simplest cannabis bill in Congress and the House hasn’t moved it.
What Happens Next
The bill sits with House leadership. There is no scheduled floor vote as of this writing. Speaker’s office has not commented publicly on timing.
There are several ways this dies without a vote: Congress runs out of legislative calendar before the next recess, the bill gets attached as a rider to larger legislation and gets stripped in conference, or leadership simply never schedules it and it lapses at the end of the 119th Congress. Any of those outcomes means starting over.
The Senate’s work is done. The clock is on the House.
Who’s Behind This
Senate Sponsors — Bipartisan Core The bill’s Senate sponsors reflect the same coalition that passed the original 2022 act: members from both parties in states with significant veteran populations, medical research infrastructure, or early-mover cannabis policy positions. The 92-4 vote means nearly every Senate Republican joined nearly every Democrat. That doesn’t happen in 2026 on anything remotely contentious.
The Four Opponents Four senators voted no. Their stated objection centers on concerns that any loosening of research restrictions on a Schedule I substance sends the wrong “cultural signal” — a phrase that has now done more legislative damage to evidence-based policy than almost any other in modern congressional history. The four have not issued detailed procedural objections; the opposition is philosophical and, at 92-4, functionally irrelevant in the Senate.
House Republican Leadership The House floor schedule is controlled by Speaker leadership and the Rules Committee. No member of that leadership team has publicly stated when or whether S.1876 will receive a floor vote. This is not an accident of scheduling. Leadership controls what gets a vote. If S.1876 isn’t scheduled, that is a decision, not an oversight.
Research Community Organizations representing academic medical centers, the Society for Neuroscience, and several veteran-focused research nonprofits have all publicly supported the bill. Their political leverage is limited — they can generate scientific credibility but not the donor pressure that moves leadership calendars.
The Bottom Line
A 92-4 Senate vote on cannabis research reform is about as close to consensus as 2026 federal legislation gets. The House not moving it within 51 days isn’t gridlock — it’s a deliberate decision about whose priorities get scheduled. For the researchers, clinicians, and patients waiting on evidence the current system has made structurally difficult to generate, the question isn’t whether the bill is popular. It is. The question is whether anyone in House leadership decides it matters enough to put on the calendar before this Congress ends.
Related Stories
Responses